Shire announces new data for hypoparathyroidism therapy
Ireland-based rare diseases leader Shire (LSE: SHP) is furthering the understanding of chronic hypoparathyroidism with data presented on new hypotheses about long-term treatment effects in patients as well as with safety and efficacy data for rhPTH (1-84) from the Open-Label RACE Study.
Shire has presented new data on recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) in patients with chronic hypoparathyroidism at the 20th European Congress of Endocrinology (ECE 2018), taking place in Barcelona, Spain.
The latest studies provide valuable insights into the burden of the disease and impact of treatment in patients with chronic hypoparathyroidism, a rare endocrine disease, according to Shire, currently the subject of a $64 billion acquisition by Japan’s Takeda Pharmaceutical (TYO: 4502).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze